Program
Hyaluronic Acid
Also written as “sodium hyaluronate 0.18%”, “Sodium hyaluronate” and “sodium hyaluronate”.
Its studies are mostly in Dry Eye Syndromes · Osteoarthritis, Knee · Osteoarthritis · Gingivitis · Keratoconjunctivitis Sicca, led by 10 companies.
Drug pageHyaluronic Acid: every studyMany companies study it; this page follows only the 17 they lead. All 195 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratorios Sophia S.A de C.V.its history only | 40 open or running | phase 4since Jan 7, 2021 | Sep 4, 2019 | none ahead |
| AbbVieits history only | 30 open or running | phase 4since Sep 25, 2008 | Sep 25, 2008 | none ahead |
| Sanofiits history only | 30 open or running | phase 4since Aug 12, 2005 | Aug 12, 2005 | none ahead |
| Daiichi Sankyoits history only | 10 open or running | phase 3since May 23, 2006 | May 23, 2006 | none ahead |
| IBSA Institut Biochimiqueits history only | 11 open or running | phase 3since Sep 9, 2026 | Sep 9, 2026 | Jun 30, 2027phase 3 · NCT07819461 |
| KLSMC Stem Cellsits history only | 10 open or running | phase 2since Mar 24, 2017 | Mar 24, 2017 | none ahead |
| Kunming Baker Norton Pharmaceutical Salesits history only | 10 open or running | phase 4since Jun 27, 2016 | Jun 27, 2016 | none ahead |
| Lantibio | 10 open or running | phase 3since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Liquidia Technologiesits history only | 10 open or running | phase 1since Nov 22, 2016 | Nov 22, 2016 | none ahead |
| TRB Chemedicaits history only | 10 open or running | phase 2since Dec 23, 2010 | Dec 23, 2010 | none ahead |
Also a collaborator on its studies: Premier Research Group and River Plate Biotechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lantibio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2008First study: phase 3 study in Dry Eye SyndromesFirst studyNCT00599716 · 300 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Lantibio leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00599716Dry Eye Syndromes · United States | 3 | Completed | Apr 2008 | 300 |
How it is read
Names in the registry
- “sodium hyaluronate 0.18%”, 2 entries
- “Sodium hyaluronate”, 2 entries
- “sodium hyaluronate”, 2 entries
- “Hyalgan (sodium hyaluronate)”, 2 entries
- “Sodium hyaluronate solution - 3.36%”, 1 entry
Codes read as this program: PRO037.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 6 studies
- Osteoarthritis, Knee, 3 studies
- Osteoarthritis, 3 studies
- Gingivitis, 1 study
- Keratoconjunctivitis Sicca, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.